NCT01559389View on ClinicalTrials.gov

Incontinence & Intimate Partners: Assessing the Contribution of Treatment

PHASE4CompletedINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

March 9, 2012

Primary Completion Date

June 29, 2017

Study Completion Date

June 29, 2017

Conditions
Urge Urinary Incontinence
Interventions
DRUG

Solifenacin

Women presenting with UUI symptoms receive 5 to 10 milligrams (mg) of daily solifenacin for up to 16 weeks

Trial Locations (1)

60153

Loyola University Medical Center, Maywood

All Listed Sponsors
collaborator

Astellas Pharma US, Inc.

INDUSTRY

lead

Loyola University

OTHER

NCT01559389 - Incontinence & Intimate Partners: Assessing the Contribution of Treatment | Biotech Hunter | Biotech Hunter